Beaucell launches stem-cell skin care
This article was originally published in The Rose Sheet
Executive Summary
Korea-based firm FCB-Pharmicell introduces Anti-Aging Regeneration Daily Program to "inspire vitality and clearness to your damaged and exhausted skin," at HBA Global Expo. Program includes a toner which "refines surface texture" and an emulsion "leaving the surface fully moist and elastic." Each contains 0.5% adult stem-cell extract. In addition, an anti-wrinkle eye cream contains yeast proteins and grain peptide to "provide elasticity and bright clearness," a cream with hexa-peptides for "flexibility" and an essence gel "for nourishment and moisture," all containing 7% adult stem-cell extract. Firm has studied anti-aging effects of stem cell media and currently has three products in IND-Phases 2 and 3 targeting acute ischemic stroke, acute myocardial infarction and spinal cord injury. Beaucell's five-product kit retails for $800 in spas
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.